1. Home
  2. CIGI vs CRSP Comparison

CIGI vs CRSP Comparison

Compare CIGI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Colliers International Group Inc. Subordinate Voting Shares

CIGI

Colliers International Group Inc. Subordinate Voting Shares

HOLD

Current Price

$109.31

Market Cap

5.8B

Sector

N/A

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$51.03

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIGI
CRSP
Founded
1972
2013
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
4.9B
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
CIGI
CRSP
Price
$109.31
$51.03
Analyst Decision
Buy
Buy
Analyst Count
5
17
Target Price
$176.25
$70.29
AVG Volume (30 Days)
174.5K
1.6M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
0.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
$17.28
$807.72
Revenue Next Year
$8.30
$172.52
P/E Ratio
$57.57
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$95.66
$33.03
52 Week High
$171.20
$78.48

Technical Indicators

Market Signals
Indicator
CIGI
CRSP
Relative Strength Index (RSI) 44.54 45.02
Support Level $97.32 $44.82
Resistance Level $120.37 $60.45
Average True Range (ATR) 3.50 2.88
MACD -0.05 -0.30
Stochastic Oscillator 13.32 12.29

Price Performance

Historical Comparison
CIGI
CRSP

About CIGI Colliers International Group Inc. Subordinate Voting Shares

Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: